ClinicalTrials.gg
Status unknownNCT01742390Updated Mar 14, 2013

A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders

A Phase 4 interventional study of Aripiprazole and risperidone or paliperidone in Sexual Dysfunction and Hyperprolactinemia, sponsored by Si Tianmei. Status unknown at 2 sites in China. Open to participants aged 12 Years to 55 Years. Per ClinicalTrials.gov, last updated 2013-03-14.

Sponsored by Si Tianmei · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2013), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
12 Years to 55 Years
Sex
All
01

Study summary

This trial designed to investigate the effect of switching to aripiprazole from risperidone or paliperidone on reverse prolactin level, and consequently improve sexual dysfunction in adult patients with schizophrenia spectrum disorders and bipolar spectrum disorders.

02

Conditions studied

  • Sexual Dysfunction
  • Hyperprolactinemia

Keywords

  • schizophrenia
  • risperidone
  • paliperidone
  • aripiprazole
03

In context

Sexual Dysfunction, Physiological

385 studies on the registry are indexed under Sexual Dysfunction, Physiological; 72 are open to participants now.

This study's planned enrollment of 120 is above the median of 72 across 263 interventional studies indexed under Sexual Dysfunction, Physiological.

Browse Sexual Dysfunction, Physiological studies →

Lead sponsor

Si Tianmei is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age: 12-55 years (male), 12-40 (female)
  2. Diagnosis: Schizophrenia spectrum disorders \& bipolar spectrum disorders (only Korea) by
  3. Receiving RIS or PALI with stable dose for > 1 month by their physician;
  4. Prolactin level Adult: > 20 ng/ml (male), 25 ng/ml (female) Child/Adolescent: > 20 ng/ml (male, female)
  5. Children and adolescents (age: 12\~17 years) having more than one sexual system dysfunction measured by 5 of the 48 UKU items (galactorrhoea, gynecomastia and erectile dysfunction for male, galactorrhea, amenorrhoea/oligomenorrhoea, and dry vagina for female) or Adults (age: 18\~55 years) who are considered to have sexual/reproductive dysfunction if they had either a total score of 19 or higher; a score of 5 or higher on one question; or a score of 4 or higher on 3 questions.
  6. Subjects who have consented to participate by signing an form.

Exclusion criteria

-

Exclusion Criteria:

  1. Medical disorder or psychiatric comorbidity or condition known to affect prolactin, sex hormone balance or bone metabolism (i.e., unstable medical disease, Cushing's disease, chronic renal failure, thyroid dysfunction, eating disorder)
  2. History of hematological and/or solid
  3. Physical or functional obstruction to food intake or impaired digestive/absorptive function
  4. Known to any study medication (risperidone, paliperidone, and aripiprazole)
  5. Insulin requiring diabetes mellitus or poorly controlled diabetes mellitus ( > 9% or change of antidiabetics treatment within the 12weeks prior to screening)
  6. Uncontrolled hypertension (SBP/DBP 140/90 mmHg), congestive heart failure ( class III or IV), other significant cardiovascular illness (myocardial infarction, unstable angina, cardiac arrhythmia etc.)
  7. Baseline of > 450 msec
  8. Hepatic and/or renal dysfunction
  1. level ≥ 1.5 upper normal limits 2) /ALT ≥ 3 UNL or 3) Serum creatinine ≥ 1.5 9. Any patient hospitalized for acute exacerbation of their condition within 2 months of randomization 10. Recent (within the past 1 month) or planned treatment with prohibited medications in the protocol

-

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Aripiprazole

    Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)

    Drug: Aripiprazole

  • Active comparator
    risperidone or paliperidone

    Stay on risperidone (RIS) or paliperidone (PALI)

    Drug: risperidone or paliperidone

Interventions

  • Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)

  • Drugrisperidone or paliperidone
06

What researchers measure

Primary outcomes

  1. Change from baseline in severity of sexual/reproductive system dysfunction at 12 weeks

    Time frame: 12 weeks

Secondary outcomes

  1. Percentage of absence of sexual/reproductive system dysfunction on the UKU side effect rating scale or ASEX

    Time frame: 12 weeks

07

Study locations

1 of 2 sites recruiting
  • Institute of mental health, Peking University
    Beijing, Beijing 100191, China
    Not yet recruiting
    • Tianmei Si, MD. · Contactsi.tian-mei@163.cm · 8610-82801948
    • Tianmei Si, MD. · Principal investigator
  • The first hospital of Hebei Province University
    Shijiazhuang, Hebei 050000, China
    Recruiting
    • Xueyi Wang, Professor · Contact0311-85917290
    • Xueyi Wang · Sub investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2013, a primary completion of Dec 2013 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2012
First posted
Dec 5, 2012
Start
Feb 2013
Primary completionEst.
Dec 2013
CompletionEst.
Jun 2014
Last update
Mar 14, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01742390
Lead sponsor
Si Tianmei
Responsible party
Si Tianmei (Professor, Peking University) — Sponsor-investigator
First posted
Dec 5, 2012
Start date
Feb 2013
Primary completion
Dec 2013 (estimated)
Completion
Jun 2014 (estimated)
Last update
Mar 14, 2013

Study contacts

Tianmei Si, MD.
Contact
si.tian-mei@163.com
861082801948

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion